Irregular Sleep Duration Tied to Increased Risk for Developing Diabetes
By Elana Gotkine HealthDay Reporter
FRIDAY, July 19, 2024 -- Irregular sleep duration is associated with elevated diabetes risk, according to a study published online July 17 in Diabetes Care.
Sina Kianersi, Ph.D., from Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues examined the association between irregular sleep duration and incident diabetes among 84,421 U.K. Biobank participants (mean age, 62 years) during seven years of follow-up.
The researchers identified 2,058 incident diabetes cases during 622,080 person-years of follow-up. After adjustment for age, sex, and race, compared with sleep duration standard deviation (SD) ≤30 minutes, the hazard ratios (95 percent confidence intervals) were 1.15 (0.99 to 1.33), 1.28 (1.10 to 1.48), 1.54 (1.32 to 1.80), and 1.59 (1.33 to 1.90) for 31 to 45, 46 to 60, 61 to 90, and ≥91 minutes, respectively. A nonlinear association was observed, with a 34 percent higher diabetes risk for individuals with a sleep duration SD of >60 versus ≤60 minutes. The association was attenuated after further adjustment for lifestyle, comorbidities, environmental factors, and adiposity (hazard ratio for sleep duration SD of >60 versus ≤60 minutes, 1.11; 95 percent confidence interval, 1.01 to 1.22). Individuals with a lower diabetes polygenic risk score and longer sleep duration had stronger associations.
"Middle-aged to older adults with inconsistent sleep duration over the week have a heightened risk of developing diabetes relative to their counterparts with more consistent sleep pattern," the authors write.
One author disclosed ties to Versalux and Delos, and is a director and founder of Circadian Health Innovations.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists
WEDNESDAY, April 30, 2025 -- Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2...
Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
WEDNESDAY, April 30, 2025 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study...
GLP-1 RAs, SGLT2 Inhibitors May Reduce Risk for Alzheimer Disease, Dementia in T2DM
THURSDAY, April 17, 2025 -- Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.